Cellectar Biosciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)	Pre-funded warrants Common Stock	Pre-funded warrants Additional Paid-In Capital	Pre-funded warrants	Tranche A Warrants Preferred Stock	Tranche A Warrants	Preferred Stock Series E-2 Preferred Stock	Preferred Stock Series E-3 preferred stock	Preferred Stock	Common Stock Series E-2 Preferred Stock	Common Stock Series E-3 preferred stock	Common Stock	Additional Paid-In Capital Series E-2 Preferred Stock	Additional Paid-In Capital Series E-3 preferred stock	Additional Paid-In Capital	Accumulated Deficit	Total
BALANCE BEGINNING at Dec. 31, 2022								$ 1,382,023			$ 94			$ 193,624,445	$ (179,499,043)	$ 15,507,519
BALANCE BEGINNING (in shares) at Dec. 31, 2022								111.11			9,385,272
Stock-based compensation														408,206		408,206
Conversion of pre-funded warrants into common shares	$ 3		$ 3
Conversion of pre-funded warrants into common shares (in shares)	355,235
Net loss															(8,581,267)	(8,581,267)
BALANCE ENDING at Mar. 31, 2023								$ 1,382,023			$ 97			194,032,651	(188,080,310)	7,334,461
BALANCE ENDING (in shares) at Mar. 31, 2023								111.11			9,740,507
BALANCE BEGINNING at Dec. 31, 2023								$ 6,059,655			$ 207			210,066,630	(217,482,539)	(1,356,047)
BALANCE BEGINNING (in shares) at Dec. 31, 2023								430.87			20,744,110
Stock-based compensation														454,363		454,363
Exercise of warrants into common shares	$ 11	$ (11)		$ 42,777,000	$ 42,777,000						$ 5			1,072,462		1,072,467
Exercise of warrants into common shares (in shares)	1,079,132			2,205.00							547,177
Conversion of pre-funded warrants into common shares						$ (1,203,346)	$ (30,555,000)		$ 9	$ 100		$ 1,203,337	$ 30,554,900			31,758,346
Conversion of pre-funded warrants into common shares (in shares)						(82.26)	(1,575.00)		903,956	9,890,099
Settlement of warrants to equity (Note 2)														4,800,000		4,800,000
Retired shares (in shares)											(8)
Net loss															(21,581,637)	(21,581,637)
BALANCE ENDING at Mar. 31, 2024								$ 17,078,309			$ 332			$ 248,151,681	$ (239,064,176)	$ 26,166,146
BALANCE ENDING (in shares) at Mar. 31, 2024								978.61			33,164,466